Immune Response in Ovarian Cancer: How Is the Immune System Involved in Prognosis and Therapy: Potential for Treatment Utilization
Figure 3
Clinical data concerning patients undertaking chemotherapy. Progression-free survival (a) and overall survival (b) of 54 patients with advanced ovarian cancer receiving first-line, platinum-based chemotherapy, according to VEGF levels in ascites. The lower levels were associated with significantly longer progression-free () and overall (). Median followup: 33 months.
